startups digital health weight loss glp-1 The Next Frontier in Healthcare Innovation – From to Whole-Body Transformation Q&A: Long-term success of GLP-1

In the SURPASS-2 head-to-head against semaglutide for diabetes, tirzepatide produced significantly greater A1c reductions

Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects

It is not intended for human consumption, therapeutic use, diagnostic use or medical application

Un nuevo estudio publicado en Jama Network Open ha relacionado el consumo de tratamientos GLP-1, similares al conocido Ozempic, en pacientes con diabetes tipo 2, con un menor riesgo de sufrir algunos tipos de cncer, vinculados a su vez con la obesidad

Eligible publications were limited to articles and reviews written in English and published between 2020 and 2025

doi:10.1056/NEJMoa1607141 Gerstein HC, Colhoun HM, Dagenais GR, et al